Schistosomiasis remains one of the neglected tropical diseases (NTDs) impacting millions of people around the world. The World Health Organization (WHO) recently proposed a goal of elimination as a public health problem (EPHP) for schistosomiasis to be reached by 2030. Current WHO treatment guidelines for achieving EPHP focus on targeting school-aged children. The NTD Modelling Consortium has developed mathematical models to study schistosomiasis transmission dynamics and the impact of control measures. Our modelling insights on Schistosoma have shown that EPHP is likely to be attainable in low to moderate mansoni prevalence settings using the current guidelines. However, as prevalence rises within higher settings, EPHP is less likely to be achieved unless both school-aged children and adults are treated (with coverage levels increasing with the adult burden of infection). We highlight the challenges that are faced by treatment programmes, such as non-adherence to treatment and resurgence, which can hinder progress towards achieving and maintaining EPHP. Additionally, even though EPHP may be reached, prevalence can still be high due to persisting infections. Therefore, without elimination of transmission, treatment will likely have to continue to maintain EPHP. Further modelling work is being carried out, including extending our results to . By providing these modelling insights, we aim to S. haematobium inform discussions on the goals and treatment guidelines for schistosomiasis.
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Background
Schistosomiasis remains an endemic neglected tropical disease (NTD) affecting approximately 220 million people worldwide 1 . It is an intestinal or urogenital disease caused predominantly by Schistosoma mansoni or S. haematobium. Individuals become infected when cercariae, released by freshwater snails, penetrate the skin during contact with contaminated water 2 . The disease can result in anaemia, chronic pain, diarrhoea, and malnutrition, causing poor school performance and lower fitness 3 . Donations of the treatment drug, praziquantel, are typically offered in school-based or community-wide mass drug administration (MDA) programmes for schistosomiasis.
The World Health Organization (WHO) has set goals of morbidity control and elimination as a public health problem (EPHP) for schistosomiasis to be reached by 2020 and 2025, respectively 4 (defined in Table 1 ). There are recommended WHO treatment guidelines for achieving these goals based on the prevalence in school-aged children (SAC; aged 5-14 years old) prior to treatment. In low prevalence settings (≤10% SAC prevalence prior to treatment), MDA once every three years is recommended; in moderate prevalence settings (10-50% SAC prevalence prior to treatment), MDA once every two years is recommended; and in high prevalence settings (≥50% SAC prevalence prior to treatment), annual MDA is recommended 4 . MDA coverage has mainly focused on reaching 75% of SAC with treatment of adults at risk also recommended. The end goal for schistosomiasis is elimination of transmission (EOT) which is achieved once the incidence of infection is reduced to zero 4 .
Mathematical models of transmission dynamics and the impact of control interventions have been developed to inform decision makers on the optimal treatment strategies which are required for achieving the WHO goals. The Gates-funded NTD Modelling Consortium brings together multiple institutional groups working on NTDs, including schistosomiasis. Modelling groups based at Imperial College London (ICL) and Case Western Reserve University (CWRU), along with other collaborators have led the recent work for schistosomiasis. A model comparison was carried out for the ICL and CWRU models, and a joint policy paper was also produced 5,6 . Due to knowledge gaps surrounding the epidemiology of schistosomiasis, the models have contrasting underlying assumptions leading to differences in model predictions 6 . Despite these differences, the models generally agree on the treatment strategies required to achieve EPHP for S. mansoni, thereby strengthening the evidence for our model recommendations 5 .
Moving towards the post-2020 goals, new WHO goals have been proposed for the NTDs to be reached by 2030. Currently, the proposed 2030 goal for schistosomiasis is EPHP. Using the insights that have been gained from recent modelling work on S. mansoni, we highlight the practical implications of EPHP (the timelines and feasibility of achieving EPHP) and the risks that need to be mitigated to maintain this goal.
Note that the following sections focus on S. mansoni and Kato-Katz (as this is the currently recommended diagnostic technique). Additionally, the current WHO treatment guidelines have been investigated here but new guidelines are currently being developed. Importantly, our modelling insights remain relevant as we highlight where the current guidelines are sufficient and where programmatic adaptations are needed for achieving EPHP (refer to Table 1 for a summary).
Insights gained from quantitative and mathematical modelling analyses
Using models developed independently by ICL and CWRU, we investigated whether the currently recommended WHO guidelines (of 75% SAC-only treatment) are sufficient for achieving the EPHP goal for S. mansoni. Our modelling and data analyses In low to moderate prevalence settings (<50% SAC prevalence prior to treatment), EPHP is likely to be achieved with 75% SAC-only treatment.
If not, what is required to achieve the goal?
As prevalence rises in high prevalence settings (≥50% SAC prevalence prior to treatment), EPHP becomes infeasible unless the disease strategy is scaled-up to treat both SAC and adults. Required coverage levels increase with the adult burden of infection.
Are current tools able to reliably measure the goal?
No; as Kato-Katz has low sensitivity at low prevalence levels, more sensitive diagnostics (able to measure prevalence and intensity of infection) will allow for smaller sample sizes and/or higher prevalence thresholds when measuring the goal.
What are the biggest unknowns?
Prevalence levels and intensity of infections across all age groups (i.e. full age profile of infection); levels of systematic non-adherence and ideal size of implementation unit; modelling insights on S. haematobium and other species.
What are the biggest risks?
Stopping treatment after achieving EPHP is highly likely to lead to resurgence of infection. Elimination of transmission (EOT) would alleviate the need for ongoing treatment. Potential risks posed by zoonotic reservoirs and drug resistance.
showed that these guidelines are sufficient for reaching EPHP in low to moderate settings 5,7 . However, as prevalence rises within high settings, an increase and expansion in treatment coverage to include adults, as well as SAC, is required to reach EPHP with coverage levels dependent on the setting 5,7 ( Table 2 ). As the burden of infection in adults relative to SAC increases, the coverage levels needed to achieve EPHP increase ( Figure 1 ) 7 . Coverage levels also increase if EPHP is to be achieved within a shorter amount of time (Figure 1 ).
Monitoring and evaluation (M&E) programmes are used to collect data to assess the progress of a treatment programme and to determine the appropriate treatment strategy. M&E data are typically collected from SAC as they are relatively easy to sample from. However, as the optimal treatment strategy for S. mansoni depends on the burden of infection in SAC and adults, M&E prevalence and infection intensity data need to be collected from a broader age-range 7 . Our work has also shown that despite achieving EPHP, the prevalence may still be high due to light-to moderate-intensity infections persisting in SAC, in addition to all the infections remaining in pre-SAC and adults 5,7 . Therefore, stopping treatment after reaching EPHP poses a high risk of resurgence.
Practical implications of the elimination as a public health problem goal
Timelines and feasibility of achieving elimination as a public health problem The treatment strategy required to achieve EPHP is determined by the epidemiological and ecological setting, such as the baseline prevalence/transmission intensity 5,7 . EPHP is technically feasible in all settings within 10 years provided that the appropriate treatment strategy is used. Table 2 shows the model recommended treatment strategies. Achieving and maintaining high coverage, adherence and treatment opportunities over each round of treatment is essential 8 . Areas with poor school enrolment may benefit more from community-wide treatment 9 . Table 2 . Model recommended treatment strategies for achieving elimination as a public health problem (EPHP) in low to high prevalence settings. SAC refers to school-aged children aged 5-14 years old.
Prevalence in SAC prior to treatment
Model recommended treatment strategy for achieving EPHP Low (<10%) 75% SAC treatment once every 3 years within 6 years 5 .
Moderate (10%-50%) 75% SAC treatment once every 2 years for up to 5 years (this holds for low to high adult burdens of infection) 7 . Note that higher settings where EPHP may not be reached will need to switch to 75% SAC annual treatment or 85% SAC and 40% adult treatment 5 .
High (≥50%)
As prevalence rises, SAC and adult annual treatment with coverage levels increasing with the adult burden of infection (coverage also increases as programme duration shortens; shown for 5-10 year programmes in Figure 1 Measuring the elimination as a public health problem goal To monitor and assess progress towards the EPHP goal, prevalence and infection intensity data are required from SAC (as the goal is defined by <1% prevalence of heavy-intensity infections in SAC). The goal is currently assessed by averaging the prevalence measured in five schools randomly sampled within a district. This approach does not take into account the high spatial heterogeneity and focality in Schistosoma prevalence.
Taking implementation decisions at the district level using the currently proposed sampling strategy can lead to underand over-treatment of SAC. Sampling fewer children in more schools has been shown to improve prevalence estimates, reducing under-treatment 10 . Ongoing work on mapping protocols will allow for more precise targeted treatment.
Kato-Katz is currently the recommended diagnostic test, but there are relatively newer, more sensitive diagnostics available. Due to the reduced sensitivity of diagnostic techniques at low prevalence levels, the true prevalence is likely to be higher than the measured prevalence. Prevalence measured with Kato-Katz will be lower relative to that measured with more sensitive diagnostics, such as point-of-care circulating cathodic antigen (POC-CCA) tests, and this difference has been analysed, although the relationship between the two diagnostics remains unclear [11] [12] [13] . Therefore, the diagnostic technique used will impact the sampling strategy, with a more sensitive diagnostic likely facilitating the sampling of fewer people or the use of higher prevalence thresholds when measuring EPHP and furthermore EOT 14 .
Considerations of cost
Accurate, representative data on which age groups are infected are required to determine the most cost-effective treatment strategy, for example, only collecting data on high-risk adults can overestimate the benefit of community-wide treatment 9 . The costs of diagnostic techniques also need to be considered. Although the traditional Kato-Katz diagnostic is seen as the cheaper test, given the increased sensitivity of POC-CCA, this may outweigh costs in the long term 15 .
Risks faced by treatment programmes
There are risks that need to be mitigated to achieve EPHP. Individuals with no access to treatment or those not taking treatment in any round of MDA (systematic non-adherers) may result in maintained transmission 8, 16 . Due to systematic non-adherence, reported coverage may be higher than true coverage 16 . Ideally data on adherence as well as coverage should be collected within M&E programmes as both will impact the outcome of treatment programmes 16 .
M&E programmes focus on SAC, and may be biased to those who are treated, making it difficult to promptly identify a failing treatment programme. Therefore, it is vital that the M&E data collected is representative of each age group 7,9 . Manipulation of implementation unit size may mask persistent prevalence of challenging locations, such as hotspots. Guidance on mapping of schistosomiasis prevalence will aid in determining the optimal size of implementation units. Further risks which may reduce the effectiveness of treatment programmes are potential drug resistance (declining praziquantel efficacy following multiple rounds of treatment 17 ) and the presence of zoonotic reservoirs 18,19 .
Following achievement of EPHP, infections may remain present in the population resulting in resurgence if treatment is stopped 5,7 . Pre-SAC can also be infected with schistosomiasis and a reservoir of infection may remain in this age group following MDA to other age groups. Development of a paediatric formulation of praziquantel for pre-SAC treatment would prevent this 20 . Due to remaining infections, it is highly likely that treatment will still be needed after achieving EPHP. Good water, sanitation and hygiene could aid in sustaining EPHP, allowing treatment to be scaled down 21 .
Moving towards elimination of transmission
To alleviate the need for ongoing treatment and to prevent resurgence, EOT is required after reaching EPHP 2,5,7 . The transition of treatment programmes from EPHP to EOT will require reassessment of the treatment strategy. Once very low prevalence levels have been achieved and a treatment programme is stopped, surveillance is needed to ensure that EOT has been achieved and that resurgence has not occurred. Currently, there is little guidance available for programmes when stopping treatment. Recently, the ICL model determined the posttreatment surveillance criteria for predicting EOT for S. mansoni. Results showed that a 1% Kato-Katz prevalence measured 2 years (or later) after stopping treatment across 200 individuals (randomly sampled from all age groups in a population of 500-1000 individuals), means EOT is 90% likely in the absence of re-introduction 14 .
Priority questions Priority issue / question identified in discussion with WHO How can quantitative and mathematical modelling address this?
Re-run the models with the broad parameters of the new treatment guidelines.
New guidelines can be simulated in the model and followed through to determine if they are sufficient for achieving EPHP (as done previously for current guidelines 5 ).
Quantitative assessment of morbidity averted with continued treatment. 
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Summary:
In this Open Letter article the authors reflect on results from quantitative and mathematical modelling that aimed to determine the impact of mass drug administration on the transmission and control of schistosomiasis and the impact of coverage in school-aged and adult populations to achieve elimination as public health problem (defined here as <1% heavy intensity infections in school-aged children) depending on the prevalence level. Challenges that schistosomiasis control programmes might face when they move towards or have achieved elimination as public health 1.
2.
3.
4.
programmes might face when they move towards or have achieved elimination as public health problem are presented. With the article, the authors aim to inform discussions on the WHO goals and treatment guidelines for schistosomiasis.
The modelling results provide important insights into whether, when and how the prevalence of schistosomiasis can be reduced and thus can well contribute to inform WHO guidelines. However, as the article is currently presented, there seems to be confusion of what the currently published (until 17.9.2019) WHO guidelines recommend and for what level of control and elimination. The authors indicate mass drug administration in school-aged children as the intervention recommended by WHO to reach elimination as public health problem. To my understanding, WHO currently recommends to "adjust preventive chemotherapy and to use additional complementary public-health interventions" for reaching elimination as a public health problem (Reference 4 of the article). Also, the Global Schistosomiasis Alliance (GSA) provided invited feedback on the new proposed WHO goals for schistosomiasis post 2020. The goal proposed by WHO on April 10, 2019 was: "Elimination as a public health problem; Criteria to measure the achievement of the goal: Proportion of heavy intensity schistosomiasis infections <1%)". The feedback from GSA on May 2nd, 2019 was "…the GSA strongly supports the proposal of the ambitious goal of interruption of transmission in selected countries and an interim and complementary goal of reducing the global It would be good if the authors can clarify on the guidelines burden of schistosomiasis disease…". and their actual content and also refer more to interruption of transmission as the ultimate goal.
Please also consider my specific comments to the manuscript and peer review form:
Is the rationale for the Open Letter provided in sufficient detail?
The rationale is provided. However, the authors might consider adding some more details. Please see my following comments: Background:
The authors write: "The World Health Organization (WHO) has set goals of morbidity control and elimination as a public health problem (EPHP) for schistosomiasis to be reached by 2020 and 2025, respectively (defined in )." The authors might consider that the WHO also set a goal Table 1 for interruption of transmission in selected countries, and present it to provide a complete picture of all goals set for 2020 and 2025.
The authors write: "There are recommended WHO treatment guidelines for achieving these goals based on the prevalence in school-aged children". The authors might consider that in their strategic plan 2012-2020, the WHO recommends to "adjust preventive chemotherapy and to use additional complementary public-health interventions" for reaching elimination as a public health problem (World Health Organization, 2013 ). Hence, in my view, the available guidelines do not focus on targeting school-aged children only. It seems to me that the authors refer to WHO recommendations for achieving morbidity control only, but not the actual guidelines for reaching elimination as public health problem. There are important differences in the approaches, which should be clarified.
The authors write: "Mathematical models of transmission dynamics and the impact of control interventions have been developed to inform decision makers on the optimal treatment strategies which are required for achieving the WHO goals". The authors might clarify which goals exactly they write about.
The authors write: "Currently, the proposed 2030 goal for schistosomiasis is EPHP." The authors 4 3 "… are sufficient for achieving the EPHP goal for . As indicated in my previous comments, S. mansoni " the current guidelines indicate that to achieve elimination of schistosomiasis as a public health problem, WHO recommends to "adjust preventive chemotherapy and to use additional complementary public-health interventions" (World Health Organization, 2013 ). Hence, it remains unclear, why the authors stick to recommendations for morbidity control and not elimination as a public health problem?
The authors write: "As the burden of infection in adults relative to SAC increases…". The authors might define burden. Is it measured in intensity, worm numbers, DALYs or something else?
Does the article adequately reference differing views and opinions?
My feeling is that some background on WHO guidelines for elimination as public health problem and interruption of transmission is missing or confused. Hence, it would be great if the authors can clarify that/why they went for modelling of morbidity control approaches rather than considering what is recommended by WHO to achieve elimination of public health problem as per the strategic plan 2012-2020.
Moreover, there is a recent trial that underlines that in a mostly low prevalence setting, 5 years of biannual MDA are not sufficient to reach elimination as a public health problem in all sentinel sites and to achieve interruption of transmission (Knopp , 2019a , Knopp , 2019b ). Additional et al. et al. operational research studies were published by members of the Schistosomiasis Consortium for Operational Research and Evaluation on controlling morbidity with different MDA approaches. The results and conclusions could be discussed in this letter in relation to the modelling results.
Are all factual statements correct, and are statements and arguments made adequately supported by citations?
The authors might want to consider the following comments (the one pertaining to the Background was already outlined above):
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